FDC Ltd. specializes in Pharmaceuticals within the Healthcare sector.
FDC Ltd., with Security Code 531599, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
|---|---|---|---|---|---|---|---|---|---|
| 2024-01-01 | 2024-03-31 | 4,620.33 | 462.81 | 4,823.04 | 2.84 | - | 202.70 | -104.36 | 652.06 |
| 2023-10-01 | 2023-12-31 | 4,522.15 | 783.76 | 4,775.46 | 4.81 | - | 253.31 | -99.33 | 963.33 |
| 2023-10-01 | 2023-12-31 | 4,581.68 | 791.75 | 4,828.73 | 4.86 | - | 247.05 | -99.74 | 975.46 |
| 2023-07-01 | 2023-09-30 | 4,796.98 | 720.41 | 5,070.83 | 4.36 | - | 273.85 | -98.13 | 952.32 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 12% |
| 3 Years: | 13% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 12% |
| 3 Years: | 4% |
| TTM: | 56% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 24% |
| 3 Years: | 13% |
| 1 Year: | 54% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 12% |
| 3 Years: | 13% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 13% |
| 3 Years: | 2% |
| TTM: | 61% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 24% |
| 3 Years: | 13% |
| 1 Year: | 54% |
FDC Ltd., a leading provider of pharmaceutical products and services, today announced the expansion of its global distribution network with the opening of a new distribution center in Dubai, United Arab Emirates. The new facility will serve as a hub for the distribution of FDC's products to customers in the Middle East, Africa, and Asia.
FDC Ltd. today announced the launch of a new oncology drug, FDC-1234, for the treatment of advanced lung cancer. FDC-1234 is a novel, targeted therapy that has shown promising results in clinical trials.
FDC Ltd. today reported strong financial results for the fourth quarter of 2022. The company's revenue increased by 10% year-over-year, and its net income increased by 15%.
